Olmesartanmedoxomil/Amlodipine Stada (Olmesartan Medoxomil, Amlodipine)

Olmesartan medoxil, the active ingredient in Olmesartanmedoxomil/Amlodipine Stada, is a angiotensin II receptor blocker presented as a fixed‑dose combination tablet for oral use. It treats hypertension, often in adults who require more than one medication to reach blood‑pressure targets. GNH USA supplies Olmesartanmedoxomil/Amlodipine Stada as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

GNH USA supplies Olmesartanmedoxomil/Amlodipine Stada as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

Olmesartan medoxil/amlodipine is indicated for management of high blood pressure within the renin‑angiotensin‑aldosterone system pathway.

- Hypertension: helps achieve target blood‑pressure levels when monotherapy is insufficient. - Hypertension with concomitant volume overload: provides additional vasodilation to improve control. - Elderly patients with hypertension: offers a convenient once‑daily regimen that can aid adherence. - Patients with isolated systolic hypertension: assists in lowering systolic pressure effectively. - Hypertensive patients with metabolic syndrome: contributes to overall cardiovascular risk reduction. - Resistant hypertension (as adjunct therapy): adds an ARB‑calcium‑channel blocker pair to overcome resistance.

Side‑effect profiles reflect the actions of both an ARB and a calcium‑channel blocker.

Common Side Effects: - Headache: mild to moderate intensity. - Peripheral edema: swelling of ankles or feet. - Dizziness or light‑headedness: especially after standing. - Flushing: transient warmth sensation. - Fatigue: general tiredness. - Nasal congestion: mild blockage of nasal passages.

Serious or Rare Side Effects: - Angio‑edema: rapid swelling of face, lips or throat. - Severe hypotension: marked drop in blood pressure. - Hepatic dysfunction: abnormal liver enzyme elevations. - Acute kidney injury: sudden reduction in renal function. - Myocardial infarction: rare but reported cardiac events. - Hyperkalemia: elevated blood potassium levels.

When prescribing Olmesartanmedoxomil/Amlodipine, clinicians should consider several safety aspects.

- Renal impairment: adjust dose or monitor renal function regularly. - Hepatic impairment: use with caution; monitor liver enzymes. - Electrolyte disturbances: check potassium levels periodically. - Pregnancy: contraindicated; avoid use in women who are pregnant or may become pregnant. - Concomitant antihypertensives: risk of additive blood‑pressure lowering. - Elderly patients: start at lower dose and titrate slowly. - Store at ambient temperature: keep in original packaging.

Olmesartanmedoxomil/Amlodipine may interact with several drug classes.

Major Interactions (Avoid): - Potassium‑sparing diuretics: may cause hyper‑kalemia. - Aliskiren (in diabetes): increased risk of renal impairment. - Strong CYP3A4 inhibitors (e.g., itraconazole): raise amlodipine levels.

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): may blunt antihypertensive effect. - Lithium: monitor serum lithium levels. - Rifampicin: may reduce amlodol